Loss of SMAD4 has been associated with worse outcomes in stage III CRC patients8, 9 and resistance to 5‐fluorouracil‐based therapy in vivo and in vitro.10, 11, 12, 13. This evidence concerns the gene SMAD4 and colorectal carcinoma.